1. Pediatric pheochromocytoma in association with Von Hippel–Lindau disease: Focus on screening strategies
- Author
-
P Y Rabattu, A. Gayot, H. Sartelet, Y. Robert, O. Chabre, P.-L. Vérot, R. Faguet, C. Piolat, and Pôle Couple-Enfant, Département de Génétique et Procréation
- Subjects
Genetic Markers ,Male ,Oncology ,endocrine system ,medicine.medical_specialty ,von Hippel-Lindau Disease ,Adolescent ,endocrine system diseases ,[SDV]Life Sciences [q-bio] ,Adrenal Gland Neoplasms ,030209 endocrinology & metabolism ,Pheochromocytoma ,Disease ,urologic and male genital diseases ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Familial predisposition ,Humans ,Von Hippel–Lindau disease ,neoplasms ,Mutation ,business.industry ,medicine.disease ,Annual Screening ,3. Good health ,Von Hippel-Lindau Tumor Suppressor Protein ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,VHL Mutation ,Age of onset ,business - Abstract
Introduction Von Hippel–Lindau disease (VHL) is a syndrome of familial predisposition to the development of malignant and benign tumours, due to mutations in the VHL tumour suppressor gene. Pheochromocytoma is a tumour that develops in the adrenal gland, rare in pediatric age, and may be associated with genetic abnormalities including mutations in the VHL gene. Systematic screening of pheochromocytoma in children carrying a VHL mutation has been proposed. However, some VHL patients who have been screened may develop symptoms associated with pheochromocytoma despite screening. Here, we report on such a case. Clinical case A 13-year-old boy, known to be a carrier of a mutation of the VHL gene, undergoing annual screening, was admitted to our hospital for clinical symptoms related to a right adrenal pheochromocytoma discovered on abdominal imaging. After hemodynamic stabilisation, the pheochromocytoma was surgically resected. Histology confirmed the diagnosis of pheochromocytoma. The postoperative care was simple. The event-free period is currently 2 years. Discussion The present case has led us to reflect on the French and international screening strategies for pheochromocytoma in children carrying a mutation of the VHL gene. Between 2013 and 2018, six different recommendations were proposed for pheochromocytoma screening in secondary prevention for children with a VHL mutation, with variability regarding the age of onset and complementary examinations to be carried out. Despite the existence of these recommendations, our case demonstrates that a pheochromocytoma can develop by escaping well-performed screening. The role of early abdominal imaging should be redefined to improve the efficiency of screening. Conclusion The discovery of a pheochromocytoma in a child must be systematically investigated for an underlying genetic cause. In the particular case of children carrying a mutation of the VHL gene, annual abdominal imaging should be included in the pheochromocytoma screening protocol from the age of 5 years.
- Published
- 2020
- Full Text
- View/download PDF